Innovation, closer to patients
Commercialising specialist medicines across Asia
One accountable regional partner, from managed access in a single market to full commercialisation across the region.
Access now. Commercialise when ready.
Our Approach
Managed Access & Named-Patient Programmes
Compliant access to medicines that are not locally registered, whether as a bridge to registration or as the long-term route for small patient populations.
Coordinated across regulatory, medical, safety and supply requirements.
Commercial Partnerships
Regional commercialisation across selected markets, from registration and market access through launch and long-term commercial management.
Why Orphidis Pharma
Your product,
a priority
A focused portfolio allows each product to receive active attention and commercial oversight
One accountable partner
One relationship and governance structure across the region, rather than managing multiple country relationships
Built for
flexibility
Start with managed access in one market or scale into broader commercialisation as the opportunity develops
High compliance & ethical standards
Quality, compliance and ethical conduct are embedded in how we select partners, govern programmes and operate across markets
Core Capabilities
What we do
Regulatory & Market Access
Registration, pricing, reimbursement and patient access
Medical
Affairs
Scientific engagement with physicians, treatment centres and healthcare stakeholders
Quality & Pharmacovigilance
Pharmacovigilance and quality oversight aligned with local regulations and partner requirements
Supply & Market Operations
Coordinated product supply and market operations
Commercial Operations
Launch planning, forecasting, commercial execution and performance management
Our markets
One region. Very different markets.
Our market focus spans South and Southeast Asia, alongside major pharmaceutical markets including Japan and South Korea.
Regulation, reimbursement, healthcare infrastructure and patient access vary significantly across the region. We build the route to market around the realities of each country and the needs of the product.
~2.5B
People across the markets shown
~4.1M
New cancer cases annually across these markets, approximately one in five worldwide
Sources: UN World Population Prospects 2024; IARC GLOBOCAN 2024.
Therapeutic focus
Therapeutic Categories
Rare Disease
Small, often underdiagnosed populations where patient identification and access are central
Oncology
Innovative cancer therapies delivered through specialist centres and hospital access pathways
Specialty Medicines
Hospital-administered and high-value therapies where specialist prescribing and access determine uptake
World Orphan Drug Alliance
WODA
Member of the World Orphan Drug Alliance
Part of an international alliance of specialist pharmaceutical companies focused on rare disease and highly specialised medicines.
